Haemonetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. 

CEO
Christopher A. Simon
CEOChristopher A. Simon
Employees
3,023
Employees3,023
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1971
Founded1971
Employees
3,023
Employees3,023

HAE Key Statistics

Market cap
2.78B
Market cap2.78B
Price-Earnings ratio
16.35
Price-Earnings ratio16.35
Dividend yield
Dividend yield
Average volume
787.15K
Average volume787.15K
High today
$60.43
High today$60.43
Low today
$58.92
Low today$58.92
Open price
$59.92
Open price$59.92
Volume
727.70K
Volume727.70K
52 Week high
$87.32
52 Week high$87.32
52 Week low
$47.32
52 Week low$47.32

Stock Snapshot

The current Haemonetics(HAE) stock price is $59.92, with a market capitalization of 2.78B. The stock trades at a price-to-earnings (P/E) ratio of 16.35.

During the trading session on 2026-03-14, Haemonetics(HAE) shares reached a daily high of $60.43 and a low of $58.92. At a current price of $59.92, the stock is +1.7% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 727.7K, compared to an average daily volume of 787.15K.

The stock's 52-week range extends from a low of $47.32 to a high of $87.32.

The stock's 52-week range extends from a low of $47.32 to a high of $87.32.

HAE News

Simply Wall St 1d
A Look At Haemonetics Valuation After Recent Share Price Weakness

Advertisement Recent performance snapshot for Haemonetics (HAE) Haemonetics (HAE) has been under pressure recently, with the share price showing a 1.9% declin...

A Look At Haemonetics Valuation After Recent Share Price Weakness
TipRanks 3d
Haemonetics price target lowered to $70 from $75 at Citi

Citi analyst Joanne Wuensch lowered the firm’s price target on Haemonetics (HAE) to $70 from $75 and keeps a Neutral rating on the shares. The firm adjusted tar...

Analyst ratings

58%

of 12 ratings
Buy
58.3%
Hold
41.7%
Sell
0%

People also own

Based on the portfolios of people who own HAE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.